Met Life Investment Management, LLC Denali Therapeutics Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 71,810 shares of DNLI stock, worth $1.54 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
71,810
Previous 71,810 -0.0%
Holding current value
$1.54 Million
Previous $1.67 Million 25.43%
% of portfolio
0.01%
Previous 0.01%

Shares

50 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$14.96 - $23.22 $142,808 - $221,658
9,546 Added 15.33%
71,810 $1.67 Million
Q1 2024

May 14, 2024
BUY
$15.83 - $23.35 $985,639 - $1.45 Million
62,264 New
62,264 $1.28 Million
Q3 2023

May 09, 2024
BUY
$20.63 - $30.17 $108,039 - $158,000
5,237 Added 9.18%
62,264 $1.28 Million
Q2 2023

Apr 29, 2024
BUY
$23.37 - $32.96 $1.46 Million - $2.05 Million
62,264 New
62,264 $1.84 Million
Q2 2023

Aug 10, 2023
BUY
$23.37 - $32.96 $122,388 - $172,611
5,237 Added 9.18%
62,264 $1.84 Million
Q1 2023

May 09, 2024
BUY
$21.91 - $32.67 $1.25 Million - $1.86 Million
57,027 New
57,027 $1.31 Billion
Q4 2022

May 10, 2024
BUY
$26.28 - $33.92 $120,888 - $156,032
4,600 Added 8.77%
57,027 $1.59 Million
Q4 2022

Mar 22, 2023
BUY
$26.28 - $33.92 $120,888 - $156,032
4,600 Added 8.77%
57,027 $1.59 Million
Q4 2022

Feb 15, 2023
BUY
$26.28 - $33.92 $120,888 - $156,032
4,600 Added 8.77%
57,027 $1.59 Million
Q3 2022

May 10, 2024
BUY
$25.97 - $38.53 $52,848 - $78,408
2,035 Added 4.04%
52,427 $1.61 Million
Q3 2022

Jun 14, 2023
SELL
$25.97 - $38.53 $119,462 - $177,238
-4,600 Reduced 8.07%
52,427 $1.61 Million
Q3 2022

Mar 22, 2023
BUY
$25.97 - $38.53 $52,848 - $78,408
2,035 Added 4.04%
52,427 $1.61 Million
Q3 2022

Nov 14, 2022
BUY
$25.97 - $38.53 $52,848 - $78,408
2,035 Added 4.04%
52,427 $1.61 Million
Q2 2022

Jun 20, 2023
SELL
$20.88 - $35.19 $138,538 - $233,485
-6,635 Reduced 11.63%
50,392 $1.48 Million
Q1 2022

May 10, 2024
BUY
$29.0 - $47.27 $1.46 Million - $2.38 Million
50,392 New
50,392 $1.62 Million
Q1 2022

Jun 20, 2023
SELL
$29.0 - $47.27 $192,415 - $313,636
-6,635 Reduced 11.63%
50,392 $1.62 Million
Q1 2022

Mar 22, 2023
BUY
$29.0 - $47.27 $522,087 - $851,001
18,003 Added 55.58%
50,392 $1.62 Million
Q1 2022

May 12, 2022
BUY
$29.0 - $47.27 $522,087 - $851,001
18,003 Added 55.58%
50,392 $1.62 Million
Q4 2021

Jun 21, 2023
SELL
$42.59 - $55.02 $1.05 Million - $1.36 Million
-24,638 Reduced 43.2%
32,389 $1.44 Million
Q3 2021

Jun 21, 2023
SELL
$48.48 - $78.23 $1.19 Million - $1.93 Million
-24,638 Reduced 43.2%
32,389 $1.63 Million
Q2 2021

May 17, 2024
BUY
$50.3 - $78.44 $383,537 - $598,105
7,625 Added 30.79%
32,389 $2.54 Million
Q2 2021

Jun 21, 2023
SELL
$50.3 - $78.44 $1.24 Million - $1.93 Million
-24,638 Reduced 43.2%
32,389 $2.54 Million
Q2 2021

Mar 22, 2023
BUY
$50.3 - $78.44 $383,537 - $598,105
7,625 Added 30.79%
32,389 $2.54 Million
Q2 2021

Aug 16, 2021
BUY
$50.3 - $78.44 $383,537 - $598,105
7,625 Added 30.79%
32,389 $2.54 Million
Q1 2021

May 17, 2024
SELL
$53.8 - $81.53 $2.02 Million - $3.06 Million
-37,500 Reduced 60.23%
24,764 $1.41 Million
Q1 2021

Jun 26, 2023
SELL
$53.8 - $81.53 $1.74 Million - $2.63 Million
-32,263 Reduced 56.57%
24,764 $1.41 Billion
Q4 2020

May 24, 2024
SELL
$36.89 - $93.56 $123,507 - $313,238
-3,348 Reduced 11.91%
24,764 $2.07 Million
Q4 2020

Jun 22, 2023
SELL
$36.89 - $93.56 $1.19 Million - $3.02 Million
-32,263 Reduced 56.57%
24,764 $2.07 Million
Q4 2020

Mar 22, 2023
SELL
$36.89 - $93.56 $123,507 - $313,238
-3,348 Reduced 11.91%
24,764 $2.07 Million
Q4 2020

Feb 16, 2021
SELL
$36.89 - $93.56 $123,507 - $313,238
-3,348 Reduced 11.91%
24,764 $2.07 Million
Q3 2020

Jun 26, 2023
SELL
$23.13 - $38.84 $668,803 - $1.12 Million
-28,915 Reduced 50.7%
28,112 $1.01 Million
Q2 2020

May 24, 2024
SELL
$16.01 - $28.82 $546,773 - $984,260
-34,152 Reduced 54.85%
28,112 $680 Million
Q2 2020

Jun 26, 2023
SELL
$16.01 - $28.82 $462,929 - $833,330
-28,915 Reduced 50.7%
28,112 $679,000
Q2 2020

Mar 22, 2023
BUY
$16.01 - $28.82 $86,806 - $156,262
5,422 Added 23.9%
28,112 $679,000
Q2 2020

Aug 14, 2020
BUY
$16.01 - $28.82 $86,806 - $156,262
5,422 Added 23.9%
28,112 $680,000
Q1 2020

Jul 12, 2023
SELL
$14.2 - $27.98 $487,585 - $960,749
-34,337 Reduced 60.21%
22,690 $397,000
Q1 2020

Mar 22, 2023
BUY
$14.2 - $27.98 $25,205 - $49,664
1,775 Added 8.49%
22,690 $397,000
Q1 2020

May 15, 2020
BUY
$14.2 - $27.98 $25,205 - $49,664
1,775 Added 8.49%
22,690 $397,000
Q4 2019

Jul 12, 2023
SELL
$14.4 - $19.99 $520,012 - $721,878
-36,112 Reduced 63.32%
20,915 $364,000
Q3 2019

Jul 12, 2023
SELL
$15.32 - $21.92 $553,235 - $791,575
-36,112 Reduced 63.32%
20,915 $320,000
Q2 2019

Jul 12, 2023
SELL
$18.5 - $28.14 $668,072 - $1.02 Million
-36,112 Reduced 63.32%
20,915 $434,000
Q1 2019

Jul 13, 2023
SELL
$17.99 - $24.65 $649,654 - $890,160
-36,112 Reduced 63.32%
20,915 $485,000
Q4 2018

Jul 13, 2023
SELL
$13.88 - $21.75 $501,234 - $785,436
-36,112 Reduced 63.32%
20,915 $432,000
Q4 2018

Mar 22, 2023
SELL
$13.88 - $21.75 $164,214 - $257,324
-11,831 Reduced 36.13%
20,915 $432,000
Q4 2018

Feb 14, 2019
SELL
$13.88 - $21.75 $164,214 - $257,324
-11,831 Reduced 36.13%
20,915 $432,000
Q3 2018

Jul 13, 2023
SELL
$12.46 - $21.74 $449,955 - $785,074
-36,112 Reduced 63.32%
20,915 $454,000
Q3 2018

Mar 22, 2023
SELL
$12.46 - $21.74 $302,541 - $527,868
-24,281 Reduced 42.58%
32,746 $711,000
Q3 2018

Nov 14, 2018
BUY
$12.46 - $21.74 $408,015 - $711,898
32,746 New
32,746 $712,000
Q2 2018

Aug 15, 2018
SELL
$15.25 - $21.02 $190,152 - $262,098
-12,469 Closed
0 $0
Q1 2018

May 15, 2018
BUY
$15.36 - $24.8 $191,523 - $309,231
12,469 New
12,469 $246,000

Others Institutions Holding DNLI

# of Institutions
227
Shares Held
119M
Call Options Held
60.6K
Put Options Held
48.4K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email